| Top 50 Most Viewed Posts This Month |
|---|
|
Today This Week Last Week This Month Last Month
|
| 1. Rosner: Short Interest Report As of Sat, Aug 3, '13 (3554) |
2. KenChowder: Here's what I find important about the new CRC (2425)  (23) |
| 3. KenChowder: My69 wrote: "ESMO, the European Society for (2259) (18) |
| 4. Jake2212: Riz: Great find re CYDY reps listed by ESMO to be (2191) (22) |
| 5. ohm20: I thought I'd better comment before this topic (2137) (23) |
| 6. Katangolo: Yes, I will never forget that he said that and he (1946) (8) |
| 7. mightycydy: CYDY's Dr. Scott Hansen & The Gates Foundation (1942) (16) |
| 8. Jake2212: Ritz: your point about only 28 mTNBC patients in (1459) (17) |
| 9. MGK_2: ohm, based on the overall survivability you've (1063) (5) |
| 10. My69z: No longer thinking my "$50b" napkin is just an (985) (6) |
| 11. My69z: Look @ this FDA accelerated approval days ago: (947) (18) |
| 12. ohm20: "In other words...Leronlimab is at LEAST 25 times (907) (13) |
| 13. MGK_2: I have a question on a (884) (2) |
| 14. ohm20: What do we think about the low mOS? Is it still a (882) (15) |
| 15. MGK_2: I think you're spot on mfglola. I wrote (865) (13) |
| 16. Riztheinvestor: ESMO calendar was this interesting tidbit. (862) (17) |
| 17. ohm20: There seems to be a couple of mistakes in that (833) (24) |
| 18. ohm20: Only 3 of the 28 patients had the optimal 700 mg (829) (8) |
| 19. Mr3Putt: Abstract for Dr. P: Presentation Number 369P (817) (18) |
| 20. My69z: Value of global oncology drugs market.... my69z (815) (14) |
| 21. My69z: Dr. Ari D. Baron @ BGT's colorectal poster find: (787) (7) |
| 22. misiu143: Great post from IHUB.. easy explanation to many (780) (26) |
| 23. Sniper: Analysis by Perplexity AI: The p-value for the (777) (22) |
| 24. hoops: "As previously announced, CytoDyn is preparing a (762) (17) |
| 25. Jake2212: The intriguing implications of hiring a new CFO (746) (25) |
| 26. Riztheinvestor: Does anything think accelerated approval is a (741) (9) |
| 27. Riztheinvestor: https://cslide.ctimeetingtech.com/gi2025/attendee (737) (19) |
| 28. My69z: Look @ ESMO from KOL perspective. These are (732) (19) |
| 29. ohm20: Do we think that Leronlimab is a time saving (731) (38) |
| 30. Riztheinvestor: https://www.dynotx.com/ Couldn’t this be our (719) (27) |
| 31. ohm20: CytoDyn Leadership Team To Attend ESMO Breast (715) (36) |
| 32. mikeyt1818: Seems like the grants keep them afloat until they (714) (4) |
| 33. grow: I don't know if this is useful to you in your (708) (10) |
| 34. sjacobs26: https://investorshangout.com/images/MYImages/1745 (705) (13) |
| 35. biloxiblues: ohm20 Great answers as usual, so I asked my (705) (11) |
| 36. Mr3Putt: should have included this info on abstract (704) (9) |
| 37. Vintool: Interesting post from Eagleforce. I am still (704) (6) |
| 38. PSU77: You're right, the quest to turn "cold" tumors (693) (32) |
| 39. MJS719: From Reddit Post It looks like CytoDyn has hired (691) (14) |
| 40. ScottyDoggs: The latest data on TNBC, and CRC must have been (689) (16) |
| 41. Riztheinvestor: We should be at .80 before any news. If something (689) (16) |
| 42. TechGuru: Sjacobs26, In preparation for the ESMO results (685) (18) |
| 43. docj: Fun to think about. Post from FB: Michael Andrew (683) (14) |
| 44. KenChowder: Here's the abstract from the Munich conference: (680) (8) |
| 45. hoops: https://www.stocktitan.net/news/CYDY/cyto-dyn-lea (673) (8) |
| 46. testuser: A Agilent Technologies AA Alcoa Inc. AAN Aaron's (661) |
| 47. jeff67: This drug, even though not getting through the (660) (11) |
| 48. ScottyDoggs: Someone on Stockwits reported that Zacks is (656) (10) |
| 49. hoops: I haven't checked IHUB for years. I notice docj (652) (6) |
| 50. brentie: From stocktwits FDA: "We're looking at (646) (10) |
